TITLE DACE

1	TITLE PAGE
2	DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-
3	INFLAMMATORY SMALL MOLECULES FOR COVID-19
4	TREATMENT USING IN SILICO AND IN-VITRO APPROACHES
5 6	Short Title: ANTIVIRAL AND ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT
7	Vladimir V. Ivanov 17, Anton B. Zakharov 1, Dmytro O. Anokhin 1, Olha O. Mykhailenko 2, Sergiy
8	M. Kovalenko ¹ , Larysa V. Yevsieieva ¹ , Victoriya A. Georgiyants ^{2*} , Michal Korinek ^{3,4} †, Yu-Li
9	Chen ⁵ , Shu-Yen Fang ^{4,6} , Mohamed El-Shazly ⁷ , Tsong-Long Hwang ^{4,5,8*} , Oleg M. Kalugin ¹
10	¹ School of Chemistry, V. N. Karazin Kharkiv National University, Kharkiv 61077, Ukraine.
11	vivanov@karazin.ua, https://orcid.org/0000- 0003-2297-9048 (V.V.I.); abzakharov@karazin.ua,
12	https://orcid.org/0000-0002-9120-8469 (A.B.Z.); dmitriy25102002@gmail.com,
13	https://orcid.org/0000-0002-4958-2692 (D.O.A.);
14	sergiy.m.kovalenko@karazin.ua, https://orcid.org/0000-0003-2222-8180 (S.M.K.);
15	lar0858@gmail.com, https://orcid.org/0000-0002-8427-7036 (L.V.Y); onkalugin@gmail.com,
16	https://orcid.org/0000-0003-3273-9259 (O.M.K.)
17	² Department of Pharmaceutical Chemistry, National University of Pharmacy, Kharkiv 61002,
18	Ukraine. o.mykhailenko@nuph.edu.ua; https://orcid.org/0000-0003-3822-8409 (O.O.M.);
19	vgeor@nuph.edu.ua; https://orcid.org/0000-0001-8794-8010 (V.A.G.)
20	³ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University,
21	Kaohsiung 80708, Taiwan. michalk@kmu.edu.tw, https://orcid.org/0000-0002-8988-8610 (M.K.)
22	⁴ Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan
23	33302, Taiwan. d1001501@cgu.edu.tw (SY.F.),
24	⁵ Graduate Institute of Health Industry Technology and Research Center for Chinese Herbal
25	Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan
26	33303, Taiwan <u>oo66931@gmail.com</u> , https://orcid.org/0000-0003-2392-1702 (YL.C.);
27	htl@mail.cgust.edu.tw, https://orcid.org/0000-0002-5780-3977 (TL.H.),
28	⁶ Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan
29	33302, Taiwan.
30	⁷ Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt.
31	mohamed.elshazly@pharma.asu.edu.eg https://orcid.org/0000-0003-0050-8288 (M.E.S.)
22	8 Department of Anasthasialagy, Chang Cyng Mamarial Hagnital, Tayyun 22205, Taiyyan

- ⁸ Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan 33305, Taiwan

* Corresponding authors: vgeor@nuph.edu.ua (V.A.G.): htl@mail.cgu.edu.tw. (T.-I.H.): Tel.: +380572-67-91-97 (V.G.); +886-3-2118800 (ext. 5523) (T.-L.H.)

† These authors contributed equally to this work

Abstract

36 37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

This study aims to develop new molecular structures as potential therapeutic agents against COVID-19, utilizing both in silico and in vitro studies. Potential targets of cepharanthine (CEP) against COVID-19 to reveal its underlying mechanism of action were evaluated using *in silico* screening experiments. A library of new molecules was docked into the receptor binding domain of the SARS-CoV-2 spike glycoprotein complex with its receptor, human ACE2, to identify promising compounds. Receptororiented docking was performed using the most likely macromolecular targets, aimed at inhibiting key viral replication pathways and reducing inflammatory processes in damaged tissues. The hit molecules showed potential inhibition of Mpro and PLpro proteases of SARS-CoV-2, which are involved in viral replication. They also showed a potential inhibitory effect on Janus kinase (Jak3), which mediates intracellular signaling responsible for inflammatory processes. The *in vitro* study examined the effects of the selected hit molecules on the generation of superoxide anions and the release of elastase in activated neutrophils, which are factors that exacerbate tissue inflammation and worsen the clinical manifestations of COVID-19. It was demonstrated that 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1,6dihydropyrimidin-2-yl)thio)-N-(3-methoxyphenyl)acetamide (Hit15) inhibited virus infection by 43.0% at 10 µM using pseudovirus assay and suppressed fMLF/CBinduced superoxide anion generation and elastase release in human neutrophils with

- 59 IC₅₀ values 1.43 and 1.28 μ M, respectively. **Hit15** showed promising activity against
- 60 coronavirus that can be further developed into a therapeutic agent.
- 61 **Keywords:** synthetic compounds, viral entry and replication, spike, SARS-CoV-2,
- 62 neutrophils

64

Introduction

- 65 The recent trends in the search for effective drugs against COVID-19 focus on the
- development of inhibitors of key SARS-CoV-2 proteins. Integrating antiviral and anti-
- 67 inflammatory therapy is a critical approach to managing COVID-19 since the
- 68 inflammation caused by the immune response leads to serious complications of the
- 69 disease [1, 2].
- 70 Understanding the pathological progression and clinical manifestations of COVID-19
- is a prerequisite for the development of drugs for rational therapeutic intervention. The
- 72 challenge of developing effective drugs to combat SARS-CoV-2 remains unresolved.
- 73 There is an urgent need for medications that can suppress the main mechanisms of
- 74 SARS-CoV-2 replication within the cell and mitigate the consequences of its impact
- on the human body [3]. This need has become especially relevant with the emergence
- of new viral variants capable of evading immune protection provided by vaccines [4,
- 77 5].
- 78 COVID-19, caused by the SARS-CoV-2 virus, is a complex, multi-organ, and
- 79 heterogeneous disease. The clinical manifestations of COVID-19 are diverse. The
- 80 disease can progress from uncomplicated forms to pneumonia and acute respiratory

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

distress syndrome (ARDS), requiring intensive care [6]. The pathogenesis of COVID-19 is driven by a hyperactive inflammatory response, leading to severe inflammation and tissue damage, particularly in the lungs [7]. It is known that excessive neutrophil activation causes tissue damage, and the neutrophil activation pathway plays a key role in the poor prognosis of COVID-19 patients by exacerbating lung inflammation and respiratory failure. Activated neutrophils secrete several cytokines, including superoxide anion, which can directly or indirectly cause tissue damage. Neutrophil elastase is a major product secreted by activated neutrophils and a key factor in tissue destruction in inflammatory diseases [8]. The inhibition of superoxide formation and elastase release, which are the markers of the anti-inflammatory response, can reduce the inflammatory burden and limit damage to the lungs and other tissues caused by COVID-19 [9]. The integration of antiviral and anti-inflammatory therapies is a key approach to managing COVID-19. This approach was initially utilized, for example, with the introduction of corticosteroids into treatment regimens to reduce the body's inflammatory response [1, 2]. In this context, there is growing interest in biologically active substances from the plant Jordanian hawksbeard, as they possess both antiinflammatory and antiviral properties. These substances inhibited the main protease of SARS-CoV-2 and reduced inflammatory processes [8, 10]. Studies confirmed the *in vitro* and *in vivo* antiviral potential of cepharanthine (CEP) against SARS-CoV-2. CEP demonstrated multiple molecular mechanisms, including the suppression of the viral entry phase (by interacting with the viral spike protein and [11, 12].

Approaches that enable the targeted creation of new pharmacologically active molecules were implemented in previous studies including computer-aided molecular modeling (CAMM) and QSAR methods [13]. In our search for new agents against SARS-CoV-2, we used workflows that combine several tools, such as pharmacophore screening of large chemical spaces and molecular docking of preselected candidates [14].

In this study, we used *in silico* screening experiments and receptor-oriented docking in the receptor binding domain of the SARS-CoV-2 Omicron spike glycoprotein complex with its receptor, human ACE2. We also used the three-dimensional structural models of other active sites of biological molecules involved in the mechanisms of SARS-CoV-2's impact on the body, using cepharanthine as a representative structure.

Materials and Methods

Computational Procedures

Molecular ligand analysis and the design of new biologically active molecules were performed using free and publicly available software packages including Jmol [15], PyMol [16], and LigandScout 4.4 [17, 18], which allowed for the pharmacophore analysis and virtual screening of specific molecular databases relative to the generated pharmacophore.

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

perpetuity.

It is made available under a CC-BY 4.0 International license. LigandScout tools [18] were used to identify the molecular parameters that would correspond to drug-like properties. Molecules with poor permeability and oral absorption (molecular weight > 500, C logP > 5, more than five hydrogen bond donors, and more than ten acceptor groups) were excluded [19]. To understand the possible mechanisms of interaction between substances and biological targets, we used the SwissTargetPrediction web server [20] to predict the biological activity of small molecules. The DataWarrior program was employed to calculate physicochemical properties and analyze molecular scaffolds [21]. **Preparation of Proteins and Database** X-ray crystal structures of the target proteins were obtained from the Protein Data Bank (PDB) [22] and used for virtual screening and receptor-oriented docking. Molecules with properties matching the pharmacophore structure constituting a set of promising molecules ("hits"), were used in the docking procedure with the active site of the corresponding target protein.

For the *in silico* virtual screening, we used a chemical space of molecules containing more than 70,000 organic compounds. The compounds of this database (DB_KSM) were synthesized by the synthetic group of Prof. S.M. Kovalenko (Department of Organic Chemistry at Kharkiv National University, Ukraine). They included various heterocyclic systems with substituents of different electronic nature, including various aliphatic fragments, amino acid residues, halogens, and others. The representative structure was cepharanthine (CEP), CAS Number 481-49-2 [23].

Molecular Docking

X-ray crystal structures of the corresponding proteins from the Protein Data Bank were used for docking. Receptor-oriented docking was performed using the AutoDock Vina program [24].

Chemistry

- The synthesis of potentially active hit compounds from virtual screening and docking experiments was carried out using previously developed methods. Hit2 [25], Hit3 Ta

 Hit5 [26], Hit9, Hit10 [27], Hit13 [28], Hit7, Hit15 [29] were prepared (Fig. 1).
 - Fig 1. Potentially active hits selected as a result of virtual screening and docking

All NMR spectra were recorded on a Varian MR-400 spectrometer with standard pulse sequences operating at 400 MHz for 1 H NMR and 101 MHz for 13 C NMR. For all NMR spectra, DMSO-d₆ was used as the solvent. Chemical shift values are referenced to residual protons ($\delta_{\rm H}$ 2.49 ppm) and carbons ($\delta_{\rm C}$ 39.6 ppm) of the solvent as an internal standard. LC/MS spectra were recorded on an ELSD Alltech 3300 liquid chromatograph equipped with a UV detector ($\lambda_{\rm max}$ 254 nm), API-150EX mass-spectrometer, and using a Zorbax SB-C18 column, Phenomenex (100 × 4 mm) Rapid Resolution HT cartridge 4.6 × 30 mm, 1.8-Micron. Elution started with 0.1 M solution of HCOOH in water and ended with 0.1 M solution of HCOOH in acetonitrile, using a linear gradient at a flow rate of 0.15 mL/min and an analysis cycle time of 25 min.

In vitro anti-inflammatory activity in human neutrophils

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

For the *in vitro* studies, the synthesized compounds (**Fig. 1**) were dissolved in dimethyl sulfoxide (DMSO) to prepare stock solutions. The final concentration of DMSO in cell experiments did not exceed 0.5% and did not affect the measured parameters. Blood was taken from healthy human donors using a protocol approved by the Chang Gung Memorial Hospital review board. Neutrophils were isolated following the standard procedure [30]. The inhibition of superoxide anion generation (respiratory burst) was measured based on ferricytochrome c reduction as previously described [31]. Briefly, preheated neutrophils (6 \times 10⁵ cells·mL⁻¹) and 0.6 mg/mL ferricytochrome c solution were treated with the tested compounds or DMSO (control) for 5 min. The cells were activated with formyl-methionyl-leucyl-phenylalanine (fMLF, 100 nM)/cytochalasin B (CB, 1 ug/mL) for 13 min. The absorbance was continuously monitored at 550 nm using Hitachi U-3010 spectrophotometer with constant stirring (Hitachi Inc., Tokyo, Japan). Calculations were based on the differences in absorbance with and without superoxide dismutase (SOD, 100 U/mL) divided by the extinction coefficient for the reduction of ferricytochrome c ($\varepsilon = 21.1/\text{mM}/10 \text{ mm}$). Elastase release (i.e., degranulation from azurophilic granules) was evaluated as described before [32]. Briefly, neutrophils were equilibrated with elastase substrate, MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide (100 μM), at 37 °C for 2 min and then incubated with the sample for 5 min. Cells were activated by 100 nM fMLF and 0.5 ug/mL CB for 13 min, and changes in the absorbance at 405 nm corresponding to

elastase release were continuously monitored. The results were expressed as the percentage of the initial rate of elastase release in the fMLF/CB-activated drug-free control system.

Pseudotyped lentivirus assay

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Lentivirus experiments were approved by the Institutional Biosafety Committee of Chang Gung University and performed according to our previous report [42]. Stable hACE-2 overexpressed HEK293T cells were provided by Dr. Rei-Lin Kuo (Chang Gung University) and maintained in DMEM containing 10 % FBS and 10 µg/mL blasticidin. VSV-G pseudotyped lentivirus control (clone name: S3w.Fluc.Ppuro) and SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses (clone name: nCoV-S-Luc-D614G and nCoV-S-Luc-B.1.617.2) were purchased from RNAi Core Facility of Academia Sinica. hACE-2 overexpressed cells (1 × 10⁴ cells/well) were seeded on 96-well plates and incubated at 37 °C with 5% CO₂. Equal relative infection units (RIU) (5 \times 10³ RIU/well= 0.5 RIU/cell) of pseudotyped lentiviruses were pretreated with various concentrations of antiviral agents in DMEM containing 5% FBS at 37 °C for 1 hour. The medium of ACE-2 overexpressed cells was replaced with treated pseudotyped lentivirus and cultured for 24 h. Luciferase activity was measured using a Luciferase Assay System (E2520, Promega) and recorded by a Fluorescence Reader. Cepharanthine served as a positive control.

WST-1 viability assay

The potential cytotoxicity of the tested samples was evaluated by the WST-1 reduction assay in hACE-2-overexpressed HEK293T [40]. The hACE-2-overexpressed HEK293T cells (1 × 10⁴ cells/well) were preincubated with DMSO or tested agents for 24 h. Then, the WST-1 reagent (M192427, Sigma-Aldrich, MO, USA) was added and incubated for 4 h at 37 °C. The absorbance at 405 nm was measured by a Multiska GO spectrophotometer (Thermo Fisher Scientific, MA, USA).

Statistical analysis

Results are expressed as mean \pm S.E.M. of two independent measurements (pseudoviral anti-viral assay) or mean \pm S.E.M. of three independent measurements (anti-inflammatory assay). The 50% inhibitory concentration (IC₅₀) was calculated from the dose-response curve obtained by plotting the percentage of inhibition versus concentrations (linear function, Microsoft Office, anti-inflammatory assay). Statistical analysis was performed using Student's *t*-test (Sigma Plot, Systat Software, Systat Software Inc., anti-inflammatory). Values with *P < 0.05, **P < 0.01, ***P < 0.001 were considered statistically significant.

Results

In silico models and calculations

Studies of the bis-benzylisoquinoline alkaloid cepharanthine (CEP) against COVID-

19 identified its significant antiviral and anti-inflammatory potential. However, the

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

precise mechanism of CEP is still under investigation [11, 12]. To model the mechanism of cepharanthine's action on COVID-19, researchers focused on various protein targets available in the Protein Data Bank (PDB). According to scientific literature, one of the primary mechanisms of CEP's action against COVID-19 is its binding to ACE2, which was validated by molecular dynamics (MD) simulations [33]. Cepharanthine was selected as the representative structure to develop new molecules with the potential to inhibit key viral pathways. The 3D crystal structure of the receptor binding domain of the SARS-CoV-2 Omicron variant spike glycoprotein complex with its receptor, human ACE2 (PDB: 7WBP), was chosen as the biological target. We conducted a preliminary pharmacophore screening using the LigandScout suite to identify suitable structures for further investigation. The receptor-binding domain of the SARS-CoV-2 Omicron spike glycoprotein complex with the human ACE2 receptor and the ligand NAG PDB 7WBP [34] was employed as a representative protein-ligand structure for the study (**Fig. 2**). Fig. 2. Receptor binding domain of SARS-CoV-2 Omicron spike glycoprotein complex with its receptor human ACE2 with ligand NAG (A), the structure of cepharanthine CEP (D) and its pharmacophore (C). The pharmacophore model CEP was used as a search query to identify compounds targeting the binding site of the biological target. Virtual screening (VS) of a molecular database (DB KSM) according to the pharmacophore identified in the previous step

resulted in identifying several compounds that could be promising in the fight against COVID-19. Based on matching with the pharmacophore, 23 compounds were selected for further study (**Fig. 3**).

Fig 3. The structures with possible activity against SARS-COV2 according to VS results of DB_KSM database.

The docking of these molecules to the receptor-binding domain of the SARS-CoV-2 Omicron spike glycoprotein complex with the human ACE2 receptor (PDB 7WBP) was performed. Their binding affinity parameters were calculated. The binding affinity scores (BAS) and binding energies (BE, kcal/mol) of the docked hit compounds, along with the co-crystallized ligand (NAG) and CEP, are presented in **Table 1**.

Table 1. Affinity parameters of hit structures (complex PDB 7WBP)

Mol	BAS	BE (kcal/mol)	Mol	BAS	BE (kcal/mol)
NAG	-2.04	-7.10	CEP	-17,54	-7,30
Hit1	-6,93	-6,60	Hit13	-17.71	-9.10
Hit2	-11.14	-8.50	Hit14	-6,88	-6,50
Hit3	-15.91	-7.90	Hit15	-10.14	-9.10
Hit4	-6,78	-7,10	Hit16	-6,56	-7,10
Hit5	-12.41	-7.60	Hit17	-6,38	-6,90
Hit6	-5,86	-7,00	Hit18	-5,85	-6,70
Hit7	-7.56	-8.60	Hit19	-5,49	-6,80
Hit8	-7,00	-6,90	Hit20	-7,13	-7,00

Hit9	-10.78	-8.50	Hit21	-6,67	-6,56
Hit10	-13.89	-8.40	Hit22	-2,54	-6,10
Hit11	-6,48	-6,90	Hit23	-4,34	-5,85
Hit12	-5,26	-7,00			

As shown in **Table 1**, eight compounds (**Hit2**, **Hit3**, **Hit5**, **Hit7**, **Hit9**, **Hit10**, **Hit13**, and **Hit15**) exhibited binding energies exceeding the absolute values of the representative cepharanthine (CEP) structure. These compounds were selected for further molecular docking studies with target proteins identified in the literature as potential pharmacological targets of cepharanthine [33].

For the calculations, hub targets for the potential pharmacological mechanism of CEP against COVID-19 were selected (**Table 2**). In the study [33], "network pharmacology" combined with RNA sequencing, molecular docking, and MD modeling was used to identify hub targets and potential pharmacological mechanisms of cepharanthine (CEP) against COVID-19. Nine key hub genes (ACE2, STAT1, SRC, PIK3R1, HIF1A, ESR1, ERBB2, CDC42, and BCL2L1) were identified. Based on these data, we performed docking studies of the home library to the hub targets from the Protein Data Bank [22] described above.

Table 2. Hub-targets and potential pharmacological mechanisms of action of cepharanthine (CEP) against COVID-19

Target	Designation	Classification
--------	-------------	----------------

1BF5	Tyrosine phosphorylated STAT-1/DNA complex	Gene regulation/DNA
1A07	C-SRC (SH2 domain) complexed with acemalonyl tyr-glu-(N,N-dipentyl amine)	Complex (transferase/peptide)
2IUI	Crystal structure of the PI3-kinase p85 N- terminal SH2 domain in complex with PDGFR phosphotyrosyl peptide	Transferase
1H2K	Factor Inhibiting HIF-1 alpha in complex with HIF-1 alpha fragment peptide	Transcription activator/inhibitor
2AJF	Structure of SARS coronavirus spike receptor-binding domain complexed with its receptor	Hydrolase / viral protein
1A52	Estrogen receptor alpha ligand-binding domain complexed to estradiol	Receptor
2A91	Crystal structure of ErbB2 domains 1-3	Signaling protein, transferase, membrane protein
7S0Y	Structures of TcdB in complex with Cdc42	Hydrolase
7JGW	Crystal structure of BCL-XL in complex with compound 1620116, crystal form 1	Apoptosis

Docking was performed using AutoDock Vina with CEP and the studied molecules. 282

The results of molecular docking and binding energies of the molecules are presented

in **Table 3**. 284

281

283

285

287

Table 3. Molecular docking binding energy results of hub genes with CEP and 286

hit-molecules

|--|

perpetuity.

It is made available under a CC-BY 4.0 International license .

1BF5	-6.0	-9.8	-9.1	-8.7	-9.3	-8.9	-9.0	-9.0	-8.7	-8.9
1A07	-7.0	-7.4	-8.1	-7.0	-8.3	-7.3	-8.8	-7.2	-8.2	-7.6
2IUI	-6.2	-9.5	-9.2	-9.3	-9.8	-8.7	-9.2	-8.9	-9.2	-8.2
1H2K	-4.3	-8.8	-8.1	-9.2	-8.4	-8.0	-8.9	-7.9	-8.6	-8.0
2AJF	-5.6	-11.1	-9.7	-9.3	-9.2	-8.8	-10.0	-8.7	-9.6	-9.0
1A52	-10.4	-8.2	-9.3	-8.4	-10.1	-8.2	-9.2	-9.4	-9.4	-8.7
1A52 2A91	-10.4 -6	-8.2 -9.7	-9.3 -9.8	-8.4 -8.4	-10.1 -8.2	-8.2 -8.9	-9.2 -10.0	-9.4 -8.8	-9.4 -8.9	-8.7 -8.2

^a Data from [33]

The molecular docking results showed a good potential for inhibition of Target 2AJF, the spike receptor-binding domain of SARS-CoV-2, in complex with its receptor and a set of targets responsible for modulating the immune response.

Additionally, we utilized the SwissTargetPrediction resource further to evaluate the most likely macromolecular targets for CEP (**Fig. 4**) and the new molecules to assess the possibility of using multiple therapeutically relevant targets for the studied compounds, as most bioactive molecules have more than one target [35].

Fig 4. The most probable macromolecular targets of CEP, suggested by the SwissTargetPrediction resource [20]

The identified biological targets for CEP included the family A G protein-coupled receptors – cell surface proteins that detect molecules outside the cell and activate

cellular responses, including immune responses. They also included the electrochemical transporters and ligand-gated ion channels responsible for signal molecule transport regulated by membrane potential or ion flow. The biological targets of the new hit compounds are presented as an aggregate bar chart (**Fig. 5**), reflecting the contribution of each category.

Fig 5. Biological target pool of the new hit molecules proposed by the SwissTargetPrediction resource [20]

The primary predicted target categories for the new hit molecules, as proposed by the SwissTargetPrediction resource, were the kinase/family A G / B G protein-coupled receptors/protease.

Table 4 presents the categories of biological targets for the new hit molecules: a) Targets responsible for modulating the immune response, which may be one of the mechanisms contributing to tissue inflammation in COVID-19 (kinases (phosphotransferases) / protein-coupled receptor A G /B G family); b) Targets from the protease category, which may be involved in inhibiting key pathways of viral replication.

Table 4. Categories of biological targets for pharmacological action against SARS-COV-2 used in the study

Target	Designation	Classification

4E4L	AK1 kinase (JH1 domain) in complex	Transferase/kinase
4D1S	Crystal structure of JAK2 kinase	Transferase/kinase
4Z16	Crystal Structure of the Jak3 Kinase Domain	Transferase/kinase
1ALU	Human Interleukin-6	Cytokine
7WOF	Crystal structure of SARS-CoV-2 Mpro	Viral protein/protease
7LLZ	Crystal structure of SARS-CoV-2 papain-like protease (PLpro)	Viral protein/protease

The results of the molecular docking, the energy characteristics of the binding affinity in kcal/mol (A), and the binding affinity score (BAS) of the studied molecules for the main predicted categories of biological targets are presented in **Table 5**.

Table 5. Results of molecular docking: Energy characteristics of binding affinity in kcal/mol (A) and binding affinity score (BAS) of the studied molecules for the main predicted categories of biological targets

Biological targets		Ligand	Hit2	Hit3	Hit5	Hit7	Hit9	Hit10	Hit13	Hit15	СЕР
4E4L	A	-11.0	-5.8	-6.9	-6.8	-8.4	-6.5	-6.4	-8.3	-6.3	-5.9
	BAS	-18.4	-14.1	-13.0	-13.6	-21.7	-29.0	-28.4	-13.8	-16.4	-10.7
4D1S	A	-10.7	-8.4	-9.6	-9.3	-9.5	-9.5	-9.5	-8.5	-9.4	-5.5
	BAS	-13.7	-14.6	-14.3	-11.0	-14.4	-17.6	-18.9	-6.2	-2.3	-10.6
4Z16	A	-8.2	-8.7	-9.5	-9.0	-6.9	-9.8	-9.4	-9.3	-9.2	-10.4
	BAS	-10.9	-18.3	-12.1	-14.7	-12.4	-13.9	-12.5	-13.3	-10.2	-10.6
1ALU	A	-4.6	-5.1	-5.9	-6.1	-6.0	-5.8	-6.1	-6.9	-5.7	-4.5
	BAS	-12,.5	-2.1	-16.8	-7.6	-15.3	-2.1	-3.2	-7.9	-1.0	-2.0

7WOF	A	-6.8	-6.4	-6.3	-6.7	-7.1	-7.6	-7.6	-7.7	-7.9	-4.9
	BAS	-14.6	-10.5	-8.8	-13.5	-6.5	-8.8	-5.4	-1.4	-13.6	9.3
7LLZ	A	-8.9	-7.8	-8.1	-8.5	-8.8	-8.0	-8.0	-8.4	-7.9	-7.3
	BAS	-20.0	-12.5	-1.1	-12.5	-16.7	-3.9	-7.3	-7.4	-13.2	-15.2

The tested molecules showed potential inhibition of Target 4Z16 (Jak3), a domain of the Janus kinase JAK3, a representative of tyrosine kinases, cytoplasmic enzymes involved in mediating intracellular signaling from cytokine receptors, which are responsible for inflammation processes [36]. Hit molecules also showed potential inhibition of SARS-COV-2 proteases Mpro and PLpro.

Several ADME parameters were calculated to evaluate the suitability of the identified compounds in terms of drug-like properties, including chemical absorption, distribution, metabolism, and excretion, which play a crucial role in determining potential drug molecules. **Table 6** presents parameters such as lipophilicity (clogP), topological polar surface area (TPSA), molecular weight (parameter SIZE, g/mol), solubility (LogS), fraction of sp3 carbon atoms (Fraction Csp3), flexibility, and optimal values of these parameters. The studied molecules conform to the drug-likeness properties.

Table 6. Drug-likeness properties of selected hits

Name	Log P _{o/w}	SIZE (g/mol)	TPSA, Å ²	LogS	Fraction C (sp³)	Flexibility	
	-0.7 <x<5.0< th=""><th>150<x<500< th=""><th>20<x<130< th=""><th>0<-X<6</th><th>0.25<x<1< th=""><th>0<x<9< th=""></x<9<></th></x<1<></th></x<130<></th></x<500<></th></x<5.0<>	150 <x<500< th=""><th>20<x<130< th=""><th>0<-X<6</th><th>0.25<x<1< th=""><th>0<x<9< th=""></x<9<></th></x<1<></th></x<130<></th></x<500<>	20 <x<130< th=""><th>0<-X<6</th><th>0.25<x<1< th=""><th>0<x<9< th=""></x<9<></th></x<1<></th></x<130<>	0<-X<6	0.25 <x<1< th=""><th>0<x<9< th=""></x<9<></th></x<1<>	0 <x<9< th=""></x<9<>	
Hit2	3.51	504.60	121.65	-4.82	0.26	12	

Hit3	5.09	442.51	90.02	-5.71	0.23	9
Hit5	4.35	462.93	90.02	-6.00	0.20	9
Hit7	5.00	389.47	97.34	-5.72	0.14	5
Hit9	3.74	438.48	137.16	-4.98	0.14	7
Hit10	3.61	450.51	116.39	-4.89	0.18	8
Hit13	1.97	435.41	122.28	-3.70	0.09	9
Hit15	3.22	473.57	151.90	-4.63	0.25	9

In vitro models

SARS-CoV-2 spike/ACE2 pseudovirus neutralization assay

The S-protein and ACE2 receptor play an essential role in the early phases of coronavirus infection [37]. The established binding assay is based on measuring luciferase activity and utilizes stable hACE-2 overexpressed HEK293T cells and SARS-CoV-2 S-protein expressing VSV-G pseudotyped lentiviruses. Omicron B1.1.529 SARS-CoV-2 coronavirus subtype was chosen as the most related subtype to the current variant. It is well known that the mutations increase the infectivity of the COVID-19 virus [38]. The cytotoxicity against hACE2-293T cells was tested, and the results revealed no toxicity (**Table 7**).

Table 7. Effects of synthetic compounds on hACE-2 overexpressed HEK293T viability

Compound	Cell viability (%) ^a			
Hit13	105.92			

Hit9	103.83				
Hit3	95.82				
Hit 7	99.47				
Hit10	96.57				
Hit5	95.19				
Hit15	97.33				
Hit2	100.00				

^a Percentage of cell at 10 μ V(n = 1). Control group (DMSO)

366

367

Next, the SARS-CoV-2 S-protein and ACE2 binding assay results showed activity of Hit15 with 43.0% inhibition at 10 μ M (Table 8). The compound possesses sulfonyl and pyrimidone moiety that may be responsible for the observed activity [39, 40].

Table 8. Effect of synthetic compounds in the pseudovirus neutralization assay of Omicron variants (SARS-CoV-2 Spike protein pseudotyped lentivirus type).

Compound	Inh% ^a				
Hit13	19.78 ± 8.29				
Hit9	2.14 ± 10.15				
Hit3	10.46 ± 5.69				
Hit 7	22.12 ± 14.37				
Hit10	14.25 ± 9.76				
Hit5	0.08 ± 6.23				
Hit15	43.00 ± 0.80				
Hit2	29.56 ± 13.34				
Cepharanthine	97.33 ± 0.08				

^a Percentage of inhibition (Inh.%) at 10 μ M. Results are presented as mean \pm S.E.M. (n = 2). Control group (DMSO). SARS-CoV-2 preudovirus strain: Omicron (B.1.1.529).

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

In the pseudovirus neutralization assay, cepharanthine showed 97.3% inhibition at 10 μ M and IC₅₀ 1.07 \pm 0.24 μ M. The antiviral potential of HIT15 and cepharanthine were in agreement with the reported data [41]. They indicated that both compounds may suppress infection of SARS-CoV-2 pseudovirus in hACE2-overexpressed host cells and may interfere with the S-protein/ACE2 binding. Previous research suggested that reducing the activity of TMPRSS2 using plant secondary metabolites could help manage COVID-19. TMPRSS2 is crucial for the virus entry stage by priming the S-protein of SARS-CoV-2, which facilitates the fusion of viral and host cell membranes. In an *in vitro* molecular docking study, cepharanthine interacted well with the TMPRSS2 and SARS-CoV-2 S-protein [43]. These data bode well with the docking result for cepharantine (**Table 3**) in the SARS-CoV-2 S-protein/ACE2 binding pocket. The anti-inflammatory activity was studied in vitro in a model of inhibition of superoxide anion release and elastase in human neutrophils. The effect of new molecules on superoxide anion generation and elastase release in activated human neutrophils was studied (Table 9). Superoxide anion generation and elastase release were induced by FMLP/CB and measured respectively. All data are expressed as mean \pm S.E.M. (n = 3-4). *P < 0.05, **P < 0.01, and ***P < 0.001 compared with the control.

Table 9. Effects of compounds on superoxide anion generation and elastase release

in fMLF/CB-induced human neutrophils

390

391

Compound	Superoxide anion				Elastase release				
	IC ₅₀ (μΜ) ^a	Inh	/ o		IC ₅₀ (μΝ	1) ^a	Inh%	D	
Hit13 ^b	>100	-4.72 ±	6.46		19.73 ±	2.39	113.52 ±	8.51	***
Hit9 ^b	>100	-0.55 ±	0.96		17.12 ±	0.19	122.94 ±	5.95	***
Hit10 ^b	>100	-0.40 ±	2.56		18.78 ±	4.25	73.21 ±	5.87	***
Hit15b	1.43 ± 0.18	100.41 ±	0.28	***	1.28 ±	0.33	114.63 ±	1.32	***
Hit5 ^c	>50	0.02 ±	1.67		>50		26.06 ±	3.28	**
Hit3d	>10	-0.61 ±	0.43		>10		22.11 ±	6.04	*
Hit7 ^d	>10	7.19 ±	2.87		>10		34.27 ±	2.90	***
Hit2d	>10	5.99 ±	2.80		>10		7.60 ±	4.78	***
LY294002e	1.76± 0.28	96.14 ±	: 1.79	***	2.23 ± 0.15		84.59 ±	2.86	***

Results are presented as mean \pm S.E.M. (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control (DMSO).

392

393

394

395

396

397

Experimental results showed that **Hit13**, **Hit9**, and **Hit10** moderately affected elastase release. **Hit15** showed good anti-inflammatory activity with IC $_{50}$ 1.76 and 2.23 μ M in both superoxide anion generation and elastase release assays in fMLF/CB-induced human neutrophils, respectively. The **Hit15** molecule has good potential for further development to treat COVID-19.

^a Concentration necessary for 50% inhibition (IC₅₀).

^b Percentage of inhibition (Inh%) at 100 μM. Compounds' solubility was 50 mM.

^c Percentage of inhibition (Inh%) at 50 µM. Compound solubility was 25 mM.

^d Percentage of inhibition (Inh%) at 10 μM. Compounds' solubility is 5 mM.

^e Positive control.

CONCLUSION

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

A virtual in silico screening and receptor-oriented docking was conducted on threedimensional structural models of active sites in biological molecules involved in the mechanisms of SARS-CoV-2 impact on the body, using cepharanthine as a representative structure. Several hit molecules were identified, characterized by binding energies with the active sites of the targets at levels comparable to or exceeding those of the representative cepharanthine structure. Receptor-oriented docking revealed that these hit molecules have the potential to inhibit SARS-CoV-2 proteases Mpro and PLpro, which play a crucial role in viral replication mechanisms, as well as to inhibit Janus kinase (Jak3), which mediates intracellular signal transduction and is responsible for inflammatory processes. The hit molecules were evaluated in vitro for anti-inflammatory activity. They were demonstrated by assessing their inhibitory effects on elastase release in human neutrophils and the generation of superoxide anions, a characteristic of antiinflammatory action. It was shown that the 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1.6-dihydropyrimidin-2-vl)thio)-N-(3-methoxyphenyl)acetamide (Hit15) exhibited potent anti-inflammatory activity. Several other molecules also demonstrated moderate effects on elastase release.

Author Contributions

419 V.A.G., V.V.I. - Conceptualization,

- 420 Y.-L.C., S.-Y.F., L.V.Y., O.M.K. Data Curation
- 421 V.A.G, O.M.K. Project Administration
- 422 V.V.I., A.B.Z., D.O.A. Software
- 423 O.M.K., T.-L.H. Supervision.
- 424 L.V.Y., V.V.I., S.M.K., M.E.-S., M.K., O.O.M. Writing original draft
- 425 V.A.G. Writing Review & Editing;
- 426 T.-L.H., O.M.K. Funding Acquisition
- 427 All authors have read and agreed to the published version of the manuscript.

Acknowledgement

428

429

430 VVI, ABZ, SMK, L.V.Y and O.M.K. express their gratitude to the National 431 Research Foundation of Ukraine (https://nrfu.org.ua/en/fundraising en/) for financial 432 support (grant No. 87/0062 (2021.01/0062) "Molecular design, synthesis and screening 433 of new potential antiviral pharmaceutical ingredients for the treatment of infectious 434 diseases COVID-19"). This research was supported by grants from the National 435 Science and Technology Council (https://www.nstc.gov.tw) (NSTC 113-2321-B-255-436 001, 113-2321-B-182-003, 112-2321-B-182-003, 112-2321-B-255-001, 111-2320-B-255-006-MY3, and 111-2321-B-255-001 granted to T.L.H.; and 113-2320-B-037-023, 437 438 112-2320-B-037-012, and 111-2320-B-037-007 granted to M.K.), Chang Gung 439 University of Science and Technology (https://english.cgust.edu.tw) (ZRRPF3L0091 440 ZRRPF3N0101) granted to T.L.H., Chang Gung Memorial Hospital (https://www.cgmh.org.tw/eng) (CMRPF1P0051-3, CMRPF1P0071-3) granted to 441

T.L.H., 442 Research Foundation and Kaohsiung Medical University 443 (https://www.kmu.edu.tw/index.php/en-gb/research) (KMU-Q113011) granted to 444 M.K., Taiwan. We thank Prof. T. Langer for the opportunity to work with the 445 LigandScout suite. 446 The funders had no role in the study design, data collection, analyses, decision 447 to publish, or manuscript preparation. 448 449 **Institutional Review Board Statement** 450 The study was conducted according to the guidelines of the Declaration of Helsinki 451 and approved by the Institutional Review Board of Chang Gung Memorial Hospital 452 (Registration number: IRB No.: 202301906A3C501), 1st August to 30th September 2024 was the recruitment period for this study. 453 454 455 **Informed Consent Statement** 456 Informed consent written and signed by donors was obtained from all subjects involved 457 in the study. No minors were included. 458 459 **Data Availability Statement** 460 All data are fully available without restriction. All relevant data are within the 461 manuscript. 462 463 **Conflicts of Interest** 464 There are no competing interests to declare.

References

466

- 1. World Health Organization. (2020). Corticosteroids for COVID-19. WHO-
- 468 2019-nCoV-Corticosteroids-2020.1-eng.pdf.
- https://iris.who.int/bitstream/handle/10665/334125/WHO-2019-nCoV-
- 470 Corticosteroids-2020.1-eng.pdf?sequence=1.
- 2. Inpatient Considerations in COVID-19 Treatment and Prevention. US
- 472 *Pharm.* 2022;47(4):HS-1-HS-7.
- 3. Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ.
- Developing New Treatments for COVID-19 through Dual-Action
- 475 Antiviral/Anti-Inflammatory Small Molecules and Physiologically Based
- Pharmacokinetic Modeling. Int J Mol Sci. 2022 Jul 20;23(14):8006. doi:
- 477 10.3390/ijms23148006. PMID: 35887353; PMCID: PMC9325261.
- 4. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S. Emerging
- SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and
- Vaccine Efficacy. Vaccines (Basel). 2021 Oct 18;9(10):1195. doi:
- 481 10.3390/vaccines9101195. PMID: 34696303; PMCID: PMC8537675
- 482 5. Aleem A, Akbar Samad AB, Vagar S. Emerging Variants of SARS-CoV-2 and
- Novel Therapeutics Against Coronavirus (COVID-19). 2023 May 8. In:
- StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
- 485 PMID: 34033342.
- 486 6. World Health Organization. (2020). Clinical care for severe acute respiratory
- 487 infection: toolkit: COVID-19 adaptation. World Health Organization.

488 https://iris.who.int/bitstream/handle/10665/331736/WHO-2019-nCoV-489 SARI toolkit-2020.1-eng.pdf 490 7. Rohilla S. Designing therapeutic strategies to combat severe acute respiratory 491 syndrome coronavirus-2 disease: COVID-19. Drug Dev Res. 2021;82:12–26 492 8. Lai KH, Chen YL, Lin MF, El-Shazly M, Chang YC, Chen PJ. Lonicerae 493 Japonicae Flos Attenuates Neutrophilic Inflammation by Inhibiting Oxidative (Basel). 494 Stress. Antioxidants 2022 Sep 9;11(9):1781. doi: 495 10.3390/antiox11091781. PMID: 36139855; PMCID: PMC9495740 496 9. Li J, Zhang K, Zhang, y. et al. Neutrophils in COVID-19: recent insights and 497 advances. Virol J **20**, 169 (2023). https://doi.org/10.1186/s12985-023-02116-498 $\mathbf{w}/$ 499 10. Anti-inflammatory, antiallergic and COVID-19 protease inhibitory activities of 500 phytochemicals from the Jordanian hawksbeard: identification, structure-501 activity relationships, molecular modeling and impact on its folk medicinal 502 **RSC** Adv., 2020,10, 38128-38141. uses. 503 https://pubs.rsc.org/en/content/articlelanding/2020/ra/d0ra04876c 11. Fan H, He ST, Han P, Hong B, Liu K, Li M, Wang S, Tong Y. Cepharanthine: 504 505 A Promising Old Drug against SARS-CoV-2. Adv Biol (Weinh). 2022 506 Dec;6(12):e2200148. doi: 10.1002/adbi.202200148. Epub 2022 Jul 1. PMID: 507 35775953; PMCID: PMC9350037 508 12. Xia B, Zheng L, Li Y, Sun W, Liu Y, Li L, Pang J, Chen J, Li J, Cheng H. The 509 brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, 510 and pharmacokinetics of cepharanthine: a potential small-molecule drug against 511 31;14:1098972. COVID-19. Pharmacol. 2023 Jul doi: Front 512 10.3389/fphar.2023.1098972. PMID: 37583901; PMCID: PMC10423819 513 13. Lengauer T, Rarey M. Computational methods for biomolecular docking. 514 Current Opinion in Structural Biology, Jun 1996, 6 (3): 402–6. 515 doi:10.1016/S0959-440X(96)80061-3. PMID 8804827 516 14. Ivanov VV, Lohachova KO, Kolesnik YV, Zakharov AB, Yevsieieva L V, 517 Kyrychenko AV, Langer T, Kovalenko SM, Kalugin ON. Recent advances in 518 computational drug discovery for therapy against coronavirus SARS-CoV-2. 519 ScienceRise: Pharmaceutical Science, 2023, DOI: 10.15587/2519-520 4852.2023.290318 521 15. Jmol: an open-source Java viewer for chemical structures in 3D. Available 522 from: http://www.jmol.org/ 523 16.DeLano WL. Pymol: An open-source molecular graphics tool. CCP4 524 Newsletter On Protein Crystallography 2002, 40: 82–92 525 17. Wolber G, Dornhofer AA, Langer T. Efficient overlay of small organic 526 molecules using 3D pharmacophores. J. Comput.-Aided Mol. Des. 2006, 20 (12): 773–788. https://doi.org/10.1007/s10822-006-9078-7 527 528 18.LigandScout. Available from: https://www.inteligand.com/ligandscout/ 529 19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and 530 computational approaches to estimate solubility and permeability in drug 531 discovery and development settings. Adv. Drug Deliv. Rev., 2012, 64: 4–17, 532 doi: 10.1016/j.addr.2012.09.019. 533 20. Swiss Target Prediction. Available from: http://swisstargetprediction.ch/.

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

21. DataWarrior. Available from: https://openmolecules.org/datawarrior/ 22. Protein Data Bank, Database [Internet]. Available from: www.rcsb.org 23. Cepharanthine. PubChem, Database [Internet]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/10206 24. AutoDock Vina. Available from: https://autodockvina.readthedocs.io/en/latest/docking basic.html 25. Tkachenko OV, Vlasov SV, Kovalenko SM, Zhuravel IO, Chernykh VP. Synthesis and the antimicrobial activity of 1-N-alkylated derivatives of 3-Nsubstituted 1H-thieno[3,2-d]pyrimidine-2,4-diones. Journal of Organic and Pharmaceutical Chemistry. 2013, 11(4): 15-21. 26. Kharchenko YV, Detistov AS, Orlov VD. Polycyclic systems containing 1,2,4oxadiazole ring. 3. 3-(1,2,4-oxadiazol-5-yl)pyridin-2(1H)-ones-synthesis and prediction of biological activity. Visnik Kharkivs'kogo Natsional'nogo Universitetu im. V. N. Karazina. 2008; 820: 216-224. 27. Borisov AV, Detistov OS, Pukhovaya VI, Zhuravel' IO, Kovalenko SM. Parallel liquid-phase synthesis of 5-(1H-4-pyrazolyl)-[1,2,4]oxadiazole libraries. Comb Chem. 2009 Nov-Dec: 11(6): 1023-9. doi: 10.1021/cc900070m. PMID: 19711964. 28. Konovalova IS, Geleverya AO, Kovalenko SM, Reiss GJ. One-pot synthesis and crystal structure of diethyl 2,6-dimethyl-4-(1-(2-nitrophenyl)-1H-1,2,3triazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate, C21H23N5O6. Zeitschrift für Kristallographie - New Crystal Structures. 2023; 2 (238): 381-384. https://doi.org/10.1515/ncrs-2022-0573

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

29. Vlasov SV, Kovalenko SM, Chernykh VP, Krolenko KY. Synthesis of 5methyl-4-thio-6-(1,3,4-oxadiazol-2-yl)thieno[2,3-d]pyrimidines and their antimicrobial activity study. Journal of Chemical and Pharmaceutical Research. 2014; 6(6): 22-27. 30. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968; 97: 77-89. 31. Korinek M, Hsieh PS, Chen YL, Hsieh PW, Chang SH, Wu YH, Hwang TL. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo. Biochem Pharmacol. 2021; 190:114596. 32. Tsai YF, Chu TC, Chang WY, Wu YC, Chang FR, Yang SC, Wu TY, Hsu YM, Chen CY, Chang SH, Hwang TL. 6-Hydroxy-5,7-dimethoxy-flavone suppresses the neutrophil respiratory burst via selective PDE4 inhibition to ameliorate acute lung injury. Free Radic Biol Med. 2017;106: 379-392. 33. Liu J. Sun T. Liu S. Liu J. Fang S. Tan S. Zeng Y. Zhang B. Li W. Dissecting the molecular mechanism of cepharanthine against COVID-19, based on a network pharmacology strategy combined with RNA-sequencing analysis, molecular docking, and molecular dynamics simulation. Comput Biol Med. 2022 Dec;151(Pt A):106298. doi: 10.1016/j.compbiomed.2022.106298. Epub 2022 Nov 11. PMID: 36403355; PMCID: PMC9671524.

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

34.PDB 7WBP. Database [Internet]. Available from: https://www.rcsb.org/structure/7WBP 35. Gfeller D, Michielin O, Zoete V. Shaping the interaction landscape of bioactive molecules. Bioinformatics. 2013 Dec 1;29(23):3073-9. doi: 10.1093/bioinformatics/btt540. Epub 2013 Sep 17. PMID: 24048355. 36. Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5. PMID: 34987201; PMCID: PMC8730299. 37. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5. PMID: 32142651; PMCID: PMC7102627. 38. Korber B. Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020/08/20/ 2020;182(4):812-827.e19. doi:https://doi.org/10.1016/j.cell.2020.06.043 39. Negi M, Chawla PA, Faruk A, Chawla V. Role of heterocyclic compounds in SARS and SARS CoV-2 pandemic. Bioorg Chem. 2020 Nov;104:104315. doi: 10.1016/j.bioorg.2020.104315. Epub 2020 Sep 24. PMID: 33007742: PMCID: PMC7513919.

601 40. Eze FU, Ezeorah CJ, Ogboo BC, Okpareke OC, Rhyman L, Ramasami P, 602 Okafor SN, Tania G, Atiga S, Ejiyi TU, Ugwu MC, Uzoewulu CP, Ayogu JI, 603 Ekoh OC, Ugwu DI. Structure and Computational Studies of New Sulfonamide 604 Compound: {(4-nitrophenyl)sulfonyl}tryptophan. Molecules. 2022 Oct 605 31;27(21):7400. doi: 10.3390/molecules27217400. PMID: 36364227; PMCID: 606 PMC9654880. 607 41. Rogosnitzky M, Okediji P, Koman I. Cepharanthine: a review of the antiviral 608 potential of a Japanese-approved alopecia drug in COVID-19. *Pharmacol Rep.* 609 Dec 2020;72(6):1509-1516. doi:10.1007/s43440-020-00132-z 610 42. Chen YL, Chen CY, Lai KH, Chang YC, Hwang TL. Anti-inflammatory and 611 antiviral activities of flavone C-glycosides of Lophatherum gracile for COVID-612 19. J Funct Foods. Feb 2023;101:105407. doi:10.1016/j.jff.2023.105407 613 43.He C-L, Huang L-Y, Wang K, et al. Identification of bis-benzylisoquinoline 614 alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. 615 Signal Transduction and Targeted Therapy. 2021/03/23 2021:6(1):131. 616 doi:10.1038/s41392-021-00531-5 617




Figure 2

Structure formula/ IUPAC Name Structure formula/ IUPAC Name N-(4-butylphenyl)-2-(2-oxo-3-(3-(p-tolyl)-N-benzyl-2-(2,4-dioxo-3-(2-oxo-2-1,2,4-oxadiazol-5-yl)pyridin-1(2H)-(phenethylamino)ethyl)-3,4yl)acetamide dihydrothieno[3,2-d]pyrimidin-1(2H)-yl)-Nethylacetamide Hit3 Hit2 medRxiv preprint doi: https://doi.org/10.1101/2024.11.06.24316825; this version posted November 11, 2024. The preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to It is made available under a N-(4-butylphenyl)-2-(3-(4-chlorophenyl)-2-(((5-methyl-2-(p-tolyl)oxazol-4-1,2,4-oxadiazol-5-yl)-2-oxopyridin-1(2H)yl)methyl)thio)-6-phenylpyrimidin-4(3H)yl)acetamide one Hit5 Hit7 2-(5-amino-3-(methylthio)-4-(3-(p-tolyl)-2-(5-amino-3-(methylthio)-4-(3-(p-tolyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)-N-(2-(4-methoxyphenyl)acetamide fluorophenyl)acetamide Hit10 Hit9 2-((5-((4-isopropylphenyl)sulfonyl)-6-oxo-1-(2-(2-fluorophenyl)-2-hydroxyethyl)-N-(4-1,6-dihydropyrimidin-2-yl)thio)-N-(3-(furan-2-carboxamido)phenyl)-1H-1,2,3triazole-4-carboxamide methoxyphenyl)acetamide

Hit15

Hit13




Figure 3




Figure 4





Figure 5



Graphical Abstract